Cargando…
Metabolomics: A New Era in the Diagnosis or Prognosis of B-Cell Non-Hodgkin’s Lymphoma
A wide range of histological as well as clinical properties are exhibited by B-cell non-Hodgkin’s lymphomas. These properties could make the diagnostics process complicated. The diagnosis of lymphomas at an initial stage is essential because early remedial actions taken against destructive subtypes...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10000528/ https://www.ncbi.nlm.nih.gov/pubmed/36900005 http://dx.doi.org/10.3390/diagnostics13050861 |
_version_ | 1784903899590688768 |
---|---|
author | Alfaifi, Abdullah Refai, Mohammed Y. Alsaadi, Mohammed Bahashwan, Salem Malhan, Hafiz Al-Kahiry, Waiel Dammag, Enas Ageel, Ageel Mahzary, Amjed Albiheyri, Raed Almehdar, Hussein Qadri, Ishtiaq |
author_facet | Alfaifi, Abdullah Refai, Mohammed Y. Alsaadi, Mohammed Bahashwan, Salem Malhan, Hafiz Al-Kahiry, Waiel Dammag, Enas Ageel, Ageel Mahzary, Amjed Albiheyri, Raed Almehdar, Hussein Qadri, Ishtiaq |
author_sort | Alfaifi, Abdullah |
collection | PubMed |
description | A wide range of histological as well as clinical properties are exhibited by B-cell non-Hodgkin’s lymphomas. These properties could make the diagnostics process complicated. The diagnosis of lymphomas at an initial stage is essential because early remedial actions taken against destructive subtypes are commonly deliberated as successful and restorative. Therefore, better protective action is needed to improve the condition of those patients who are extensively affected by cancer when diagnosed for the first time. The development of new and efficient methods for early detection of cancer has become crucial nowadays. Biomarkers are urgently needed for diagnosing B-cell non-Hodgkin’s lymphoma and assessing the severity of the disease and its prognosis. New possibilities are now open for diagnosing cancer with the help of metabolomics. The study of all the metabolites synthesised in the human body is called “metabolomics.” A patient’s phenotype is directly linked with metabolomics, which can help in providing some clinically beneficial biomarkers and is applied in the diagnostics of B-cell non-Hodgkin’s lymphoma. In cancer research, it can analyse the cancerous metabolome to identify the metabolic biomarkers. This review provides an understanding of B-cell non-Hodgkin’s lymphoma metabolism and its applications in medical diagnostics. A description of the workflow based on metabolomics is also provided, along with the benefits and drawbacks of various techniques. The use of predictive metabolic biomarkers for the diagnosis and prognosis of B-cell non-Hodgkin’s lymphoma is also explored. Thus, we can say that abnormalities related to metabolic processes can occur in a vast range of B-cell non-Hodgkin’s lymphomas. The metabolic biomarkers could only be discovered and identified as innovative therapeutic objects if we explored and researched them. In the near future, the innovations involving metabolomics could prove fruitful for predicting outcomes and bringing out novel remedial approaches. |
format | Online Article Text |
id | pubmed-10000528 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-100005282023-03-11 Metabolomics: A New Era in the Diagnosis or Prognosis of B-Cell Non-Hodgkin’s Lymphoma Alfaifi, Abdullah Refai, Mohammed Y. Alsaadi, Mohammed Bahashwan, Salem Malhan, Hafiz Al-Kahiry, Waiel Dammag, Enas Ageel, Ageel Mahzary, Amjed Albiheyri, Raed Almehdar, Hussein Qadri, Ishtiaq Diagnostics (Basel) Review A wide range of histological as well as clinical properties are exhibited by B-cell non-Hodgkin’s lymphomas. These properties could make the diagnostics process complicated. The diagnosis of lymphomas at an initial stage is essential because early remedial actions taken against destructive subtypes are commonly deliberated as successful and restorative. Therefore, better protective action is needed to improve the condition of those patients who are extensively affected by cancer when diagnosed for the first time. The development of new and efficient methods for early detection of cancer has become crucial nowadays. Biomarkers are urgently needed for diagnosing B-cell non-Hodgkin’s lymphoma and assessing the severity of the disease and its prognosis. New possibilities are now open for diagnosing cancer with the help of metabolomics. The study of all the metabolites synthesised in the human body is called “metabolomics.” A patient’s phenotype is directly linked with metabolomics, which can help in providing some clinically beneficial biomarkers and is applied in the diagnostics of B-cell non-Hodgkin’s lymphoma. In cancer research, it can analyse the cancerous metabolome to identify the metabolic biomarkers. This review provides an understanding of B-cell non-Hodgkin’s lymphoma metabolism and its applications in medical diagnostics. A description of the workflow based on metabolomics is also provided, along with the benefits and drawbacks of various techniques. The use of predictive metabolic biomarkers for the diagnosis and prognosis of B-cell non-Hodgkin’s lymphoma is also explored. Thus, we can say that abnormalities related to metabolic processes can occur in a vast range of B-cell non-Hodgkin’s lymphomas. The metabolic biomarkers could only be discovered and identified as innovative therapeutic objects if we explored and researched them. In the near future, the innovations involving metabolomics could prove fruitful for predicting outcomes and bringing out novel remedial approaches. MDPI 2023-02-23 /pmc/articles/PMC10000528/ /pubmed/36900005 http://dx.doi.org/10.3390/diagnostics13050861 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Alfaifi, Abdullah Refai, Mohammed Y. Alsaadi, Mohammed Bahashwan, Salem Malhan, Hafiz Al-Kahiry, Waiel Dammag, Enas Ageel, Ageel Mahzary, Amjed Albiheyri, Raed Almehdar, Hussein Qadri, Ishtiaq Metabolomics: A New Era in the Diagnosis or Prognosis of B-Cell Non-Hodgkin’s Lymphoma |
title | Metabolomics: A New Era in the Diagnosis or Prognosis of B-Cell Non-Hodgkin’s Lymphoma |
title_full | Metabolomics: A New Era in the Diagnosis or Prognosis of B-Cell Non-Hodgkin’s Lymphoma |
title_fullStr | Metabolomics: A New Era in the Diagnosis or Prognosis of B-Cell Non-Hodgkin’s Lymphoma |
title_full_unstemmed | Metabolomics: A New Era in the Diagnosis or Prognosis of B-Cell Non-Hodgkin’s Lymphoma |
title_short | Metabolomics: A New Era in the Diagnosis or Prognosis of B-Cell Non-Hodgkin’s Lymphoma |
title_sort | metabolomics: a new era in the diagnosis or prognosis of b-cell non-hodgkin’s lymphoma |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10000528/ https://www.ncbi.nlm.nih.gov/pubmed/36900005 http://dx.doi.org/10.3390/diagnostics13050861 |
work_keys_str_mv | AT alfaifiabdullah metabolomicsanewerainthediagnosisorprognosisofbcellnonhodgkinslymphoma AT refaimohammedy metabolomicsanewerainthediagnosisorprognosisofbcellnonhodgkinslymphoma AT alsaadimohammed metabolomicsanewerainthediagnosisorprognosisofbcellnonhodgkinslymphoma AT bahashwansalem metabolomicsanewerainthediagnosisorprognosisofbcellnonhodgkinslymphoma AT malhanhafiz metabolomicsanewerainthediagnosisorprognosisofbcellnonhodgkinslymphoma AT alkahirywaiel metabolomicsanewerainthediagnosisorprognosisofbcellnonhodgkinslymphoma AT dammagenas metabolomicsanewerainthediagnosisorprognosisofbcellnonhodgkinslymphoma AT ageelageel metabolomicsanewerainthediagnosisorprognosisofbcellnonhodgkinslymphoma AT mahzaryamjed metabolomicsanewerainthediagnosisorprognosisofbcellnonhodgkinslymphoma AT albiheyriraed metabolomicsanewerainthediagnosisorprognosisofbcellnonhodgkinslymphoma AT almehdarhussein metabolomicsanewerainthediagnosisorprognosisofbcellnonhodgkinslymphoma AT qadriishtiaq metabolomicsanewerainthediagnosisorprognosisofbcellnonhodgkinslymphoma |